Algeria has taken a significant step in its fight against cancer with the opening of a new manufacturing unit for monoclonal antibodies in Oran. The facility was inaugurated on Thursday, June 18th, by the Minister of Pharmaceutical Industry, Ouacim Kouidri. This development marks a turning point for Algerian medicine, reducing reliance on imports for this critical cancer treatment component. Monoclonal antibodies are key in targeted cancer therapies, offering a more precise approach to treatment. The new unit aims to improve access to these vital medications for Algerian patients. Further details regarding the facility’s capacity and specific antibody types produced were not immediately available. This initiative represents Algeria’s commitment to strengthening its domestic pharmaceutical industry and healthcare infrastructure.